Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease

[1] Baumgart DC(2012)Crohn's disease Lancet 380 1590-1605

[2] Sandborn WJ(2020)Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study Lancet Gastroenterol. Hepatol. 5 475-484

[3] Olen O(2020)Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014 Gut. 69 453-461

[4] Erichsen R(2020)Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden Aliment Pharmacol. Ther. 52 655-668

[5] Sachs MC(2018)Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden Gastroenterology. 154 518-528

[6] Olen O(2014)Temporal trends in non- stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study J. Crohns Colitis 8 1653-30

[7] Askling J(2014)Optimizing anti-TNF treatments in inflammatory bowel disease Autoimmun. Rev. 13 24-366

[8] Sachs MC(2010)Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects J. Crohns Colitis. 4 355-197

[9] Khalili H(2015)Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse Inflamm. Bowel Dis. 21 182-51

[10] Everhov AH(2016)Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management Aliment Pharmacol. Ther. 43 30-767

[1] Baumgart DC(2012)Crohn's disease Lancet 380 1590-1605

[2] Sandborn WJ(2020)Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study Lancet Gastroenterol. Hepatol. 5 475-484

[3] Olen O(2020)Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014 Gut. 69 453-461

[4] Erichsen R(2020)Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden Aliment Pharmacol. Ther. 52 655-668

[5] Sachs MC(2018)Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden Gastroenterology. 154 518-528

[6] Olen O(2014)Temporal trends in non- stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study J. Crohns Colitis 8 1653-30

[7] Askling J(2014)Optimizing anti-TNF treatments in inflammatory bowel disease Autoimmun. Rev. 13 24-366

[8] Sachs MC(2010)Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects J. Crohns Colitis. 4 355-197

[9] Khalili H(2015)Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse Inflamm. Bowel Dis. 21 182-51

[10] Everhov AH(2016)Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management Aliment Pharmacol. Ther. 43 30-767